Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Follitropin Alfa (recombinant FSH) bulk supplier for pharma manufacturers

Follitropin Alfa (Recombinant Fsh) Suppliers & Bulk Manufacturers

Available Forms: Prefilled Pen/Vial

Available Strengths: 50 IU, 75 IU, 100 IU, 150 IU, 200 IU, 300 IU, 450 IU, 900 IU

Reference Brands: Gonal-f® (EU & US), Ovaleap®, Bemfola®(EU), Follistim AQ®(US)

Category: Women's Health

Follitropin Alfa injections are high-purity recombinant FSH used in fertility treatments like IVF. Leading US & EU brands include Gonal-f, Follistim AQ, Bemfola, and Ovaleap, available in 50 IU to 900 IU strengths. Sourced from FDA- and EMA-approved facilities, these injections are ideal for clinics and fertility centers seeking quality, consistency, and reliable supply.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description: Leading B2B pharmaceutical suppliers in the US and EU offer Follitropin Alfa injections, a recombinant FSH hormone widely used in IVF and fertility treatments. Trusted brands include Gonal-f, Follistim AQ, Bemfola, and Ovaleap, available in prefilled pens, cartridges, and vials with strengths ranging from 50 IU to 900 IU. These FDA- and EMA-approved products provide accurate, controlled ovarian stimulation with high purity and consistency. Suitable for clinics, hospitals, and fertility centers, all formulations meet strict GMP standards. Partner with verified distributors for reliable access to premium Follitropin Alfa across Europe and the United States.

Follitropin Alfa (Recombinant Fsh) — third party manufacturing & bulk supply

Follitropin Alfa (Recombinant Fsh) is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Follitropin Alfa (Recombinant Fsh) is supplied as Prefilled Pen/Vial — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Follitropin Alfa (Recombinant Fsh) listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Follitropin Alfa (Recombinant Fsh) →
Back to Listing

Frequently Asked Questions

Follitropin Alfa (recombinant FSH) is listed as Prefilled Pen/Vial in 50 IU, 75 IU, 100 IU, 150 IU, 200 IU, 300 IU, 450 IU, 900 IU. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Follitropin Alfa (recombinant FSH) is referenced against Gonal-f® (EU & US), Ovaleap®, Bemfola®(EU), Follistim AQ®(US). Reference brands are shown for identification only and remain the property of their respective trademark owners.

Related Products

Somatropin

Strength:
5 mg/1.5 mL, 10 mg/1.5 mL, 15 mg/1.5 mL

Form: injection (prefilled syringe)

Reference Brands: Genotropin (EU), Norditropin (EU/India)

View Details
Nafarelin Acetate

Strength:
2 mg/mL

Form: Nasal Spray

Reference Brands: Synarel (USA)

View Details
Ospemifene

Strength:
60 mg

Form: Tablets

Reference Brands: Osphena (USA/EU)

View Details
Elagolix

Strength:
150 mg, 200 mg

Form: Tablets

Reference Brands: Orilissa (USA),

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.